Drug Safety
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Rheumatology Round-Up with Drs. Kavanaugh & Cush
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020.
Vaneet K Sandhu, MD vksandhumd
4 years 7 months ago
ARCH study -- n~4100
Romo vs Alendronate x 12 mo
Alendronate 12-24 mo
RRR 38% https://t.co/d0G7x4TqUT
The Lancet TheLancet
4 years 7 months ago
Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of major cardiovascular outcomes in patients with gout: finding from FAST, multicentre, prospective, randomised, open-label, non-inferiority trial https://t.co/cpoNi7zjwi https://t.co/uQyeyepPmj
Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed a black-box warning on the medication’s label suggesting that it increases the risk of cardiovascular (CV) death in patients with preexisting CV disease.
As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.
New ACR RA Guidelines and Practice Changing Abstracts: RA Panel
Dr. Jonathan Kay leads an international panel on the new ACR RA guidelines and other practice-changing abstracts presented at the 2020 ACR annual meeting. Panelists include Dr.Kathryn Dao, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway and Dr. Sheila Reyes.
Cardiovascular Safety for Feboxustat with Dr. Nicola Dalbeth
Auckland's Dr. Dalbeth examines the cardiovascular safety in the FAST trial of feboxustat (abstract L08) presented at the ACR 2020.
Adverse Events in Low-Dose Methotexate: Dr. Eric Dein
Dr. Eric Dein reviews abstract #2001 presented at the 2020 ACR annual meeting.
Dr. Tom Appleton and Dr. Peter Nash Highlight OA and PsA Studies
Dr. Janet Pope interviews Dr. Tom Appleton and Dr. Peter Nash about several osteoarthritis and psoriatic arthritis studies presented at the 2020 ACR annual meeting.
Richard Conway RichardPAConway
4 years 7 months ago
Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in RA patients in sustained remission. 63% of tapered patients flared over 12 months vs 5% of maintained. Good response to reintroduction of TNFi @rheumnow #ACR20 Abstr#2010 https://t.co/Ki7PTsetbH
Dr. Ken Saag - RECIPE Study: MMF with Pegloticase
Dr. Jack Cush interviews Dr. Ken Saag about the benefits of adding mycophenolate to your pegloticase regimen in refractory gout patients.
Robert B Chao, MD doctorRBC
4 years 7 months ago
COX2 inhibitors associated with inhibition of radiographic spinal progression in AxSpA pts compared to non-selective NSAIDs.
⬇️radiographic spinal progression over 2 yrs
⬇️mSASSS progression
@RheumNow #ACR20 Abs#2030 https://t.co/p1CeNBm3ma
k dao KDAO2011
4 years 7 months ago
The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF were not allowed in this study (vs. CARES trial where all subjects had baseline CVD); I am still cautious prescribing febuxostat to pts who have severe CVD until we have more data. @RheumNow https://t.co/fJ9bLcXpR2
Dr. John Cush RheumNow
4 years 7 months ago
IN GOUT: CARES study said febuxostat increases CV risk; Todays FAST study says No incr CV risk w/ FEB. In your Gout pt w/ CV hx, would you use febuxostat? #ACR2020
Poster Hall